Sichuan University
Clinical trials sponsored by Sichuan University, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New triple therapy shows promise for tough lung cancer Results expected Dec 2026 (estimated)
- Engineered immune cells take aim at Hard-to-Treat lung cancer Results expected Dec 2026 (estimated)
- New hope for aggressive lung cancer: drug cocktail plus Low-Dose radiation shows promise Results expected Dec 2026 (estimated)
- Radiation boosts immunotherapy in lung cancer trial Results expected Feb 2027 (estimated)
- New Three-Drug cocktail aims to wipe out stomach cancer before surgery Results expected May 2027 (estimated)
-
New radiation combo aims to boost immunotherapy in advanced lung cancer
Disease control OngoingThis early-phase trial tests whether adding low-dose radiation and targeted radiation (SBRT) to an immunotherapy drug (PD-1 inhibitor) is safe for people with stage IV non-small cell lung cancer who have not responded to standard treatments. About 9 participants will receive the …
Phase 1 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for aggressive lung cancer: drug cocktail plus Low-Dose radiation shows promise
Disease control OngoingThis study tests a new combination treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. It combines an experimental immunotherapy (AK104) with standard chemotherapy and low-dose radiation to see if it can better control the cancer. The …
Phase 1/2 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Triple threat: Low-Dose radiation plus chemo and immunotherapy takes on tough lung cancer
Disease control OngoingThis phase 2 trial is testing a new approach for people with extensive-stage small cell lung cancer who have not had prior treatment. It combines low-dose radiation with standard chemotherapy (cisplatin or carboplatin plus etoposide) and the immunotherapy drug serplulimab. The go…
Phase 2 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Lung cancer combo therapy study pulled before starting
Disease control CancelledThis early-stage study aimed to test a new combination treatment for people with extensive-stage small cell lung cancer who had not received prior therapy. The approach combined low-dose radiation with standard chemotherapy and two immunotherapy drugs (toripalimab and tifcemalima…
Phase 1 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC